Special Issue "Nanotechnology Applied in Prevention, Diagnosis and Treatment of Cancer"

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".

Deadline for manuscript submissions: 31 December 2023 | Viewed by 722

Special Issue Editor

Department of Biotechnology and Bioengineering, Kangwon National University, Chuncheon 24341, Republic of Korea
Interests: cancer; infectious diseases; nanoencapsulation; nanomedicine; nanoparticles; new drug delivery systems; polymersome; theragnosis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cancer is a major global health issue. Indeed, despite significant progress made in the fields of cancer research and treatment, there remains a need for more effective and precise diagnostic tools and treatment options. Nanotechnology, the manipulation of materials at the nanoscale level, has the potential to revolutionize cancer care by offering innovative approaches for prevention, diagnosis, and treatment. Nanoparticles can be engineered to selectively target cancer cells while minimizing side effects, whether as drug carriers or imaging agents. In cancer prevention, nanotechnology may help to reduce the incidence of the disease by developing novel approaches to address risk factors and early detection. The impact of nanotechnology in cancer care has shown promising results in preclinical and clinical studies. However, further research and development are necessary to realize its full potential in cancer care. Nanotechnology presents a unique opportunity to develop more effective and precise cancer therapies, which may in turn lead to better outcomes for patients.

We look forward to receiving your contributions.

Dr. Hyun-ouk Kim
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanoparticles
  • drug delivery
  • biosensors
  • imaging
  • theragnosis

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Article
Development of a Gold Nanoparticle-Linked Immunosorbent Assay of Staphylococcal Enterotoxin B Detection with Extremely High Sensitivity by Determination of Gold Atom Content Using Graphite Furnace Atomic Absorption Spectrometry
Pharmaceutics 2023, 15(5), 1493; https://doi.org/10.3390/pharmaceutics15051493 - 13 May 2023
Viewed by 432
Abstract
Highly sensitive staphylococcal enterotoxin B (SEB) assay is of great importance for the prevention of toxic diseases caused by SEB. In this study, we present a gold nanoparticle (AuNP)-linked immunosorbent assay (ALISA) for detecting SEB in a sandwich format using a pair of [...] Read more.
Highly sensitive staphylococcal enterotoxin B (SEB) assay is of great importance for the prevention of toxic diseases caused by SEB. In this study, we present a gold nanoparticle (AuNP)-linked immunosorbent assay (ALISA) for detecting SEB in a sandwich format using a pair of SEB specific monoclonal antibodies (mAbs) performed in microplates. First, the detection mAb was labeled with AuNPs of different particle sizes (15, 40 and 60 nm). Then the sandwich immunosorbent assay for SEB detection was performed routinely in a microplate except for using AuNPs-labeled detection mAb. Next, the AuNPs adsorbed on the microplate were dissolved with aqua regia and the content of gold atoms was determined by graphite furnace atomic absorption spectrometry (GFAAS). Finally, a standard curve was drawn of the gold atomic content against the corresponding SEB concentration. The detection time of ALISA was about 2.5 h. AuNPs at 60 nm showed the highest sensitivity with an actual measured limit of detection (LOD) of 0.125 pg/mL and a dynamic range of 0.125–32 pg/mL. AuNPs at 40 nm had an actual measured LOD of 0.5 pg/mL and a dynamic range of 0.5 to 128 pg/mL. AuNPs at 15 nm had an actual measured LOD of 5 pg/mL, with a dynamic range of 5–1280 pg/mL. With detection mAb labeled with AuNPs at 60 nm, ALISA’s intra- and interassay coefficient variations (CV) at three concentrations (2, 8, and 20 pg/mL) were all lower than 12% and the average recovery level was ranged from 92.7% to 95.0%, indicating a high precision and accuracy of the ALISA method. Moreover, the ALISA method could be successfully applied to the detection of various food, environmental, and biological samples. Therefore, the successful establishment of the ALISA method for SEB detection might provide a powerful tool for food hygiene supervision, environmental management, and anti-terrorism procedures and this method might achieve detection and high-throughput analysis automatically in the near future, even though GFAAS testing remains costly at present. Full article
Show Figures

Figure 1

Back to TopTop